Cargando…

Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China

BACKGROUND: The cost-effectiveness of human papillomavirus (HPV) vaccination in women pre-sexual debut has been demonstrated in many countries. This study aimed to estimate the cost-effectiveness of a 3-dose bivalent HPV vaccination at ages 12 to 55 year in both rural and urban settings in China. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yi-Jun, Zhang, Qian, Hu, Shang-Ying, Zhao, Fang-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768405/
https://www.ncbi.nlm.nih.gov/pubmed/26919850
http://dx.doi.org/10.1186/s12885-016-2207-3
_version_ 1782417942687776768
author Liu, Yi-Jun
Zhang, Qian
Hu, Shang-Ying
Zhao, Fang-Hui
author_facet Liu, Yi-Jun
Zhang, Qian
Hu, Shang-Ying
Zhao, Fang-Hui
author_sort Liu, Yi-Jun
collection PubMed
description BACKGROUND: The cost-effectiveness of human papillomavirus (HPV) vaccination in women pre-sexual debut has been demonstrated in many countries. This study aimed to estimate the cost-effectiveness of a 3-dose bivalent HPV vaccination at ages 12 to 55 year in both rural and urban settings in China. METHODS: The Markov cohort model simulated the natural history of HPV infection and included the effect of screening and HPV vaccination over the lifetime of a 100,000 female cohort. Transition probabilities and utilities were obtained from published literature. Cost data were estimated by Delphi panel using healthcare payers’ perspective. Vaccine cost was assumed Hong Kong listed price. Vaccine efficacy (VE) was based on the PATRICIA trial data assuming VE irrespective of HPV type at all ages on incident HPV. Costs and outcomes were discounted at 3 %. Cervical cancer cases and incremental cost-effectiveness ratio (ICER) for vaccination and screening compared with screening alone were estimated for each vaccination age. Reduced VE in women post-sexual debut were investigated in scenario analyses. RESULTS: With 70 % vaccination coverage, a reduction of cancer cases varying from 585 to 33 in rural and 691 to 32 in urban were estimated at ages 12 to 55, respectively. The discounted ICERs of vaccination at any age under 23 years in rural and any age under 25 years in urban were lower than the current threshold. Scenario analyses with lower VE post-sexual debut confirmed the results with age 20 in rural and 21 in urban had consistent lower ICERs. The more ‘catch-up’ cohorts vaccinated at the start of a program, the more cancer lesions are avoided in the long-term. CONCLUSIONS: Vaccination at any age under 23 years old in rural and any age under 25 years old in urban were cost-effective. Catch-up to the age of 25 years in rural and urban could still be cost-effective. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2207-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4768405
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47684052016-02-27 Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China Liu, Yi-Jun Zhang, Qian Hu, Shang-Ying Zhao, Fang-Hui BMC Cancer Research Article BACKGROUND: The cost-effectiveness of human papillomavirus (HPV) vaccination in women pre-sexual debut has been demonstrated in many countries. This study aimed to estimate the cost-effectiveness of a 3-dose bivalent HPV vaccination at ages 12 to 55 year in both rural and urban settings in China. METHODS: The Markov cohort model simulated the natural history of HPV infection and included the effect of screening and HPV vaccination over the lifetime of a 100,000 female cohort. Transition probabilities and utilities were obtained from published literature. Cost data were estimated by Delphi panel using healthcare payers’ perspective. Vaccine cost was assumed Hong Kong listed price. Vaccine efficacy (VE) was based on the PATRICIA trial data assuming VE irrespective of HPV type at all ages on incident HPV. Costs and outcomes were discounted at 3 %. Cervical cancer cases and incremental cost-effectiveness ratio (ICER) for vaccination and screening compared with screening alone were estimated for each vaccination age. Reduced VE in women post-sexual debut were investigated in scenario analyses. RESULTS: With 70 % vaccination coverage, a reduction of cancer cases varying from 585 to 33 in rural and 691 to 32 in urban were estimated at ages 12 to 55, respectively. The discounted ICERs of vaccination at any age under 23 years in rural and any age under 25 years in urban were lower than the current threshold. Scenario analyses with lower VE post-sexual debut confirmed the results with age 20 in rural and 21 in urban had consistent lower ICERs. The more ‘catch-up’ cohorts vaccinated at the start of a program, the more cancer lesions are avoided in the long-term. CONCLUSIONS: Vaccination at any age under 23 years old in rural and any age under 25 years old in urban were cost-effective. Catch-up to the age of 25 years in rural and urban could still be cost-effective. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2207-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-02-26 /pmc/articles/PMC4768405/ /pubmed/26919850 http://dx.doi.org/10.1186/s12885-016-2207-3 Text en © Liu et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Liu, Yi-Jun
Zhang, Qian
Hu, Shang-Ying
Zhao, Fang-Hui
Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China
title Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China
title_full Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China
title_fullStr Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China
title_full_unstemmed Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China
title_short Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China
title_sort effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768405/
https://www.ncbi.nlm.nih.gov/pubmed/26919850
http://dx.doi.org/10.1186/s12885-016-2207-3
work_keys_str_mv AT liuyijun effectofvaccinationageoncosteffectivenessofhumanpapillomavirusvaccinationagainstcervicalcancerinchina
AT zhangqian effectofvaccinationageoncosteffectivenessofhumanpapillomavirusvaccinationagainstcervicalcancerinchina
AT hushangying effectofvaccinationageoncosteffectivenessofhumanpapillomavirusvaccinationagainstcervicalcancerinchina
AT zhaofanghui effectofvaccinationageoncosteffectivenessofhumanpapillomavirusvaccinationagainstcervicalcancerinchina